Somewhat Positive Press Coverage Somewhat Unlikely to Affect NeoGenomics (NEO) Stock Price
News headlines about NeoGenomics (NASDAQ:NEO) have trended somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. NeoGenomics earned a media sentiment score of 0.22 on Accern’s scale. Accern also assigned media headlines about the medical research company an impact score of 46.8162801970963 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.
These are some of the media headlines that may have effected Accern’s scoring:
- Next Century Growth Investors LLC Sells 905,209 Shares of NeoGenomics, Inc. (NEO) (americanbankingnews.com)
- Form 4 NEOGENOMICS INC For: Feb 26 Filed by: SHOVLIN ROBERT J. – StreetInsider.com (streetinsider.com)
- NeoGenomics, Inc. (NEO) Shares Sold by Hudson Bay Capital Management LP (americanbankingnews.com)
- NeoGenomics, Inc. (NEO) Holdings Cut by Cortina Asset Management LLC (americanbankingnews.com)
- Royce & Associates LP Sells 60,000 Shares of NeoGenomics, Inc. (NEO) (americanbankingnews.com)
A number of equities research analysts have recently weighed in on NEO shares. Royal Bank of Canada set a $23.00 target price on NeoGenomics and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. BidaskClub downgraded NeoGenomics from a “buy” rating to a “hold” rating in a report on Thursday, December 21st. Scotiabank set a $22.00 target price on NeoGenomics and gave the stock an “outperform” rating in a report on Wednesday, January 3rd. CIBC set a $19.00 target price on NeoGenomics and gave the stock a “neutral” rating in a report on Wednesday, January 3rd. Finally, Zacks Investment Research raised NeoGenomics from a “sell” rating to a “hold” rating in a report on Friday, February 23rd. Five equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $15.83.
NeoGenomics (NASDAQ:NEO) last posted its earnings results on Wednesday, February 21st. The medical research company reported $0.04 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.02 by $0.02. NeoGenomics had a positive return on equity of 4.37% and a negative net margin of 1.37%. The company had revenue of $67.79 million during the quarter, compared to the consensus estimate of $66.32 million. During the same quarter last year, the firm earned $0.05 earnings per share. The company’s revenue was up 12.1% on a year-over-year basis. research analysts forecast that NeoGenomics will post 0.09 EPS for the current fiscal year.
NeoGenomics Company Profile
NeoGenomics, Inc is an operator of a network of cancer-focused genetic testing laboratories. The Company operates in Laboratory Testing Segment. This segment delivers testing services to hospitals, pathologists, oncologists, other clinicians and researchers. It has laboratory locations in Ft. Myers and Tampa, Florida; Aliso Viejo, Fresno, Irvine, and West Sacramento, California; Houston, Texas and Nashville, and Tennessee.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.